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Introduction 
Inhaled corticosteroids, such as beclomethasone dipropio- 
nate (BDP), are well recognized as the most effective anti- 
inflammatory drugs currently available for the treatment of 
chronic asthma. Research to obtain effective and well- 
tolerated asthma therapies has led to improvements in the 
delivery systems and formulations of inhaled corticoster- 
oids and to the development of new steroid agents. 
This article outlines the history of inhaled steroids from 
early studies with BDP to the recent advances in inhaled 
corticosteroid therapy. It then goes on to examine the relative 
clinical effectiveness of the new and improved formulation of 
BDP, hydrofluoroalkane- 134a (HFA)-BDP extrafine aerosol, 
with the new steroid, fluticasone propionate (FP). 
Development of inhaled steroid 
therapy 
The introduction of inhaled beclomethasone dipropionate 
nearly 30 years ago (1,2) radically altered the management 
of asthma. Prior to the 197Os, patients with asthma were 
frequently prescribed oral steroids and suffered the 
predictable systemic side-effects. 
After an initial unfavourable clinical trial in Edinburgh, 
the development of inhaled BDP nearly ceased. Subsequent 
trials, however, showed that BDP was effective. In these 
early studies, the efficacy of an inhaled steroid was 
expressed in terms of the facility in chronic steroid- 
dependent asthmatics to allow reduction of oral steroid 
therapy. BDP at a dose of 400 pg day-’ produced uniform 
results in patients with chronic asthma, showing an oral 
steroid sparing effect equivalent to between 5-lOmgday-’ 
of prednisolone (Table 1). A fuller description of the detail 
of this early work is available in a comprehensive review by 
Mygind and Clark (3). 
Improvements in inhaled 
corticosteroid therapy 
The past 30 years haveseen the application of theory to the 
practical management of asthma. There has been an 
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increase in the diagnosis of the disease and a general 
increase in inhaled steroid usage. There have also 
been important advances in delivery systems and in 
formulations, for example, the new extrafine aerosol 
preparation of BDP in which BDP is present in a solution 
of HFA propellant (I-IFA-BDP extrafine aerosol; 
QVARTM, 3M Pharmaceuticals, St Paul, MN, U.S.A.). 
This has proved to be a major improvement in the 
formulation of BDP, resulting in the need for approxi- 
mately half the dose of the previous, conventional chloro- 
fluorocarbon (CFC) formulation to achieve similar 
improvements in asthma symptoms (4-7). 
While larger doses of BDP may be needed for the 
treatment of more severe asthma, systemic side-effects may 
become evident at doses of above lOOOpgday-’ (8). 
Concern about the long-term side-effects of inhaled 
corticosteroids has led physicians to a strategy of combin- 
ing a modest dose of an inhaled corticosteroid with bther 
drugs, such as long-acting bronchodilators. In adults, the 
maximum recommended aily dose of HFA-BDP extrafine 
aerosol is 800 fig day-’ (9). ‘_ 
Improvements in the steroid molecule have taken 
longer to emerge than changes in BDP formulations and 
delivery systems. FP was introduced in the early 199Os, 
particularly for patients requiring high doses of conven- 
tional CFC-BDP. It is one of the most potent inhaled 
steroids currently available (10) and has more potent ,anti- 
inflammatory effects in vitro (11) and in vivo (12) than BDP. 
Fluticasone propionate is more lipophilic than BDP and 
has a longer tissue half-life than beclomethasone-l7- 
monopropionate, the active m&abolite of BDP (10). These 
properties suggested that fluticasone propionate would 
prove to be a major therapeutic advance in asthma therapy. 
The characteristic of having effectively no absorption 
by mouth was predicted to lead to fewer systemic side- 
effects. 
In a meta-analysis of clinical trials in patients with 
asthma of all severities, the efficacy of FP in the treatment 
of asthma was shown, perhaps disappointingly, to be only 
equivalent to twice the dose of conventional CFC-BDP 
throughout the dose range (400-2000 pgday-‘) (13). In an 
earlier study of adults with severe asthma, lOOOpgday-’ 
FP. was shown to be as effective as 2000pgday-’ CFC- 
BDP (14). More recently, a nebulized preparation of FP 
given at a dose of 2OOOpg twice daily has been reported to 
only have an oral steroid effect equivalent to 4.4 mg day- * 
prednisolone (15). 
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TABLE 1. Clinical trials showing the oral steroid sparing 
effect of inhaled beclomethasone dipropionate 
Clinical trial 
BDP Prednisolone 
(pgday-‘1 (mgday-‘) 
Brown et al. (1972) 
Clark (1972) (27) 
Lal ef al. (1972) (2) 
Cameron et nl. (1973) (28) 
British Thoracic and Tubercu- 
losis Association (1975) (29) 
Brompton Hospital/Medical 
Research Council (1974) (30) 
Brompton Hospital/Medical 
Research Council (1974) (30) 
Cooper and Grant (1977) (31) 
400 7.5-10.0 
400 10.0 
300 7.0-8.0 
400 5.0 
400 7.5 
400 54-9-o 
800 7.5-10.0 
400 5.0-6.0 
Source: Ref. 3. 
HFA-BDP extrafine aerosol compared 
with fluticasone propionate 
HFA-BDP extrafine aerosol has been shown to be as 
effective as twice the dose of conventional CFC-BDP in the 
treatment of moderate asthma. This therapeutic ratio is 
likely to be due to the greatly improved deposition of HFA- 
BDP extrafine aerosol into the airways of the lung 
compared with CFC-BDP (16). This improvement prob- 
ably results from the difference in particle size and 
dynamics between the two formulations: HFA-BDP has a 
smaller particle size than CFC-BDP (16) and a lower 
velocity spray force. (17). As a result, a smaller fraction of 
the total dose of HFA-BDP extrafine aerosol is deposited in 
the larynx and upper respiratory tract compared with 
conventional CFC-BDP (16) and therefore less drug is 
swallowed. Theoretically, this should result in fewer adverse 
effects in tissues outside the lung. 
In contrast to HFA-BDP, fluticasone propionate has 
been reported to achieve an in vitro lung deposition of only 
20% in a mechanical lung model, with the remainder of the 
dose being deposited in the oropharynx and larynx (Fig. 1) 
(18). The oral systemic bioavailability of FP is very low and 
there is a high first-pass metabolism (19) so the incidence of 
systemic side-effects caused by swallowed drug should be 
minimal. The local steroid side-effects in the larynx are still 
important. Although dysphonia is a well-recognized com- 
plication of inhaled CFC-BDP therapy (20) it appears to 
be more common with FP than with CFC-BDP, possibly 
because FP has greater glucocorticoid receptor potency. 
Overall, dysphonia has been observed in 2% of adults on 
FP compared to 1% on CFC-BDP (21). In another study 
following the use of a higher (1500 pg day- ‘) dose of FP for 
one year, dysphonia occurred in 6% of adults (22). 
Recently, the more serious adverse effect of fungal 
colonisation of the larynx (laryngeal aspergillosis) has been 
described when 2000 pgday- ’ FP was administered for 
3 years (23). 
Lung Oropharynx Exhaled 
FIG. 1. Drug deposition of HFA-BDP extrafine aerosol 
(particle size 1.1 pm: 0) and FP (particle size 2.0 pm: n ) 
in the mechanical lung. 
Clinical studies of HFA- 
beclomethasone dipropionate 
extrafine aerosol vs. fluticasone 
propionate 
On the basis that HFA-BDP extrafine aerosol has been 
shown to have approximately 2-2.6 times the comparative 
dose ratio of conventional CFC-BDP (6) it could be 
predicted that HFA-BDP extrafine aerosol and FP would 
prove to be equipotent in the control of asthma. The 
objective of two recent studies, which directly compared 
HFA-BDP extrafine aerosol with FP in chronic asthma, 
was to confirm this predicted equivalence in the clinical 
setting (24,25) (Table 2). 
In the first of these studies (24) we compared 
400 pg day- ’ HFA-BDP with 400pgday-’ CFC-FP in 
adults with asthma that was not adequately controlled on 
previous inhaled corticosteroid therapy of 200- 
500 pg day-’ CFC-BDP or equivalent. (The most common 
dose of CFC-BDP used in general practice for the 
treatment of moderate asthma is 400pgday-‘.) This was 
a randomized, double-blind, double-dummy, parallel-group 
study conducted in the U.K. and Ireland predominantly in 
patients from general practice (Table 2). Following a 5- 
9 day run-in period to assess igns and symptoms of 
asthma, -patients were randomized to 400 pg day- ’ HFA- 
BDP (n=88) or 400pgday-’ FP (n=84) for 6 weeks. The 
groups were well matched with no significant differences 
between them, including the prestudy doses of inhaled 
corticosteroid. Mean change from baseline in morning 
(AM) peak expiratory flow (PEF) at week 6 was the 
primary efficacy variable. AM PEF in both the HFA-BDP 
extrafine aerosol and FP groups improved significantly 
compared with baseline values and there was no significant 
difference between the two groups (Fig. 2). At weeks 5-6, 
the mean change from baseline in AM PEF was 
19.0 lmin-’ for HFA-BDP extrafine aerosol and 
30.5 lmin- ’ for FP and the two groups were shown to be 
equivalent [90% confidence interval (CI) was -22.47 to 
-0.59; P=O.O22]. No difference between the two groups 
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TABLE 2. Clinical trials of hydrofluoroalkane beclomethasone dipropionate (HFA-BDP) vs. fluticasone propionate (FP) 
Study 1 - low dose comparison Study 2 - high dose comparison 
(24) (25) 
Patients 
Design 
Duration 
Location 
Adults with symptomatic moderate 
asthma 
Double-blind, double-dummy, 
parallel group multicentre study 
6 weeks 
U.K. and Northern Ireland 
Treatment 
groups 
400 pg day-’ HFA-BDP (n=88) 
400pgday-’ FP (n=84) 
Adults with symptomatic moderate to 
severe asthma 
Open-label, parallel group 
multicentre study 
8 weeks 
France, Belgium, Germany, 
The Netherlands 
800 /Ig day- ’ HFA-BDP (n= 10 I) 
IOOOpgday-’ HFA-FP (n=97) 
I 
Of I I I I 
Baseline weeks l-2 Weeks 34 Weeks 5-6 
0.7 
.j 0.6 
2 0.5 
j 0.4 
%J 1 0.3 
” 0.2 
j 0.1 
0 
FIG. 2. Mean (SE) AM PEF (lmin-‘) for HFA-BDP 
extrafine aerosol (- - - -: 400 pg) and FP (-: 400 pg) 
(Study 1, Ref. 24). ‘Significant equivalence (P=O.536 for 
difference) (equivalence limit k2.5 I min- ‘. 
was observed when looking at mean percentage change 
from baselinein FEVl (2.51% and 5.39% for HFA-BDP 
extrafine aerosol and FP, respectively; P=O.381). Both 
groups showed similar improvements in symptoms of 
asthma, such as wheeze, cough, breathlessness, chest 
tightness and sleep disturbance. Both inhaled steroids led 
to a decrease in daily p-agonist usage with no differences 
between treatments. Using the Asthma Quality of Life 
Questionnaire (26), no differences between HFA-BDP 
extrafine aerosol and FP were seen overall or for each of 
the four domains (Fig. 3). Thus, 400pgday-’ HFA-BDP 
extrafine aerosol was shown to be equivalent to 
400 pg day- ’ FP. In addition, patients changing from 
200-500pgday-’ CFC-BDP (or equivalent) to approxi- 
mately the same dose of HFA-BDP extrafine aerosol 
experienced improved asthma control. 
In the second study (25), Wettengel ef al. compared the 
efficacy and safety of HFA-BDP extrafine aerosol and 
HFA-FP at higher doses. This multicentre study (con- 
ducted in France, Belgium, Germany and The Netherlands) 
was similar in design to the low-dose study described above, 
although it was an open-label comparison using HFA-BDP 
extrafine aerosol (800pgday-‘) and the new HFA for- 
mulation of FP (lOOOpgday- ‘) and for a slightly longer 
period of 8 weeks. Patients were symptomatic on their 
Overall Symptoms Emotions Environment Activities 
FIG. 3. Mean (SE) change from baseline in Asthma Quality 
of Life Questionnaire score at week 6 for HFA-BDP 
extrafine aerosol (0: 400 pg) and FP ( n : 400 pg) (Study 1, 
Ref. 24). 
previous therapy of 500-IOOOpgday-’ CFC-BDP, or 
equivalent, prior to randomization. Patients received either 
800 pg day- ’ HFA-BDP (n=lOl) or lOOOpgday-’ HFA- 
FP (n=97) for 8 weeks. The two groups were well matched. 
At week 8, mean AM PEF (the primary efficacy variable) 
had markedly improved from baseline in both groups; 
mean change from baseline at week 8 was 29.59 1 min- ’ for 
HFA-BDP and 17.13 1 min- ’ HFA-FP (a difference of 
+ 12.46lmin;-’ 90% CI -0.02, 24.91) (Fig. 4). This 
demonstrated that both groups had the capacity to show 
improvement in pulmonary function. However, as there 
appeared to be a greater than anticipated difference 
between the two treatment groups, a further analysis using 
the per-protocol population was carried out in order to test 
for any clinical difference between them. This population is 
a subset of the ITT population and comprises all those 
patients who had no major protocol violations, were 
compliant with the study medication and completed a 
study diary card. 
In the per-protocol population (n=121) the mean change 
from baseline in AM PEF at week 8 was significantly 
greater in the QVAR group compared with the HFA-FP 
group (P<O.Ol). At week 8, the mean change in AM PEF 
was 34.84 Imin-’ in the QVAR group and 20.63 1 min-’ in 
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FIG. 4. Mean (SE) change from baseline in AM PEF 
(lmin-‘) for HFA-BDP extrafine aerosol and FP (Study 
2, Ref. 25). -I-: HFA-BDP 8OOpg; -A-: HFA-FP 
1000 pg. ‘Significant change from baseline (P < 0.05); 
+Significant equivalence (90% CI -0.02, 24.91) 
(equivalence limit * 25 1 min-‘). 
0 12 3 4 5 6 7 8 
Week 
FIG 5. Mean change from baseline in AM PEF (Imin-‘) 
- per protocol analysis. -m-: QVAR 800 pg day-’ 
(n=58); -A-: HFA-FP 1000 pg day-’ (n=63). 
l Signi8cant change within treatment group from baseline 
@‘<O-05); “significant change within treatment group 
from baseline (Pt O*0 1); tsignificant difference between 
treatment groups (PcO.01). 
the HFA FP group, with a difference of 14.21 Imin- ’ (90% 
CI; 2.66, 31.10) (Fig 5). 
Similarly, FEVl had improved from baseline at week 8 
and there was no difference between treatments in mean 
change from baseline for this parameter. In addition, there 
were no statistically significant differences between the 
groups in the mean change from baseline in percentage of 
days without wheeze, cough, shortness of breath or chest 
tightness, or nights without sleep disturbance at weeks 3 
and 8. However, at week 3, the mean (SE) change from 
baseline in percentage of days free from daily asthma 
symptoms was significantly greater in the HFA-BDP group 
compared with the HFA-FP group [18.32% (3.4%) vs. 
6.84% (2.6%); P=O.O3]. This trend was maintained at week 
8, although the difference was no longer significant [24.32% 
(4.39%) vs. 18.20% (4.0%); P=O.23]. At week 8, improve- 
ments from baseline were reported for asthma symptoms 
(wheeze, cough, breathlessness, chest tightness, all daytime 
FIG. 6. Mean change from baseline in percentage of days/ 
nights without asthma symptoms/sleep disturbance at 
week 8 for HFA-BDP extrafine aerosol and FP (Study 2, 
Ref. 25). n : HFA-BDP 800pgday-’ (n=lOl); IJ: HFA- 
FP lOOOpgday-’ (n=97). *P<O.O5 within treatment 
group change from baseline; l 'P<O.Ol within treatment 
group change from baseline; +number of days without any 
daytime asthma symptom (no wheeze, no cough, no 
shortness of breath, no chest tightness). 
symptoms, and sleep disturbance) in both groups and the 
difference between treatments was not statistically signifi- 
cant (Fig. 6). In addition, there was a similar reduction in 
bronchodilator usage in both groups; the difference 
between treatments was not significant. Thus, 800 pg day-’ 
HFA-BDP extrafine aerosol provides equivalent asthma 
control to lOOOpgday-’ HFA-FP in patients with moder- 
ate-to-severe symptomatic asthma. 
In these two relatively short-term studies, the incidence of 
individual treatment-related adverse events was similarly 
low for both HFA-BDP extrafine aerosol and FP (Table 3). 
For HFA-BDP, the most commonly reported treatment- 
related adverse event in both studies was oropharyngeal 
fungal infection, reported by 2.3% of patients in study 1 
and 4.0% of patients in study 2. For CFC-FP (study 1) 
inhalation site sensation (2.4%) and cough (2.4%) were the 
most commonly reported treatment-related adverse events. 
For HFA-FP (study 2), fungal infection, inhalation site 
sensation and dysphonia were the most common, each one 
occurring in 3.1% of patients. 
Conclusion 
In conclusion, for patients with inadequately controlled 
asthma, a change from previous inhaled corticosteroid 
therapy to HFA-beclomethasone dipropionate extrafine 
aerosol or fluticasone propionate may result in an 
improvement in asthma control. Low doses (400 pg day-‘) 
of FP and HFA-BDP extrafine aerosol appear to be equally 
effective. In addition, at higher doses, HFA-BDP extrafine 
aerosol (800pgday-‘) appears to be as effective as HFA- 
FP (1000 pgday-‘). The choice between these two inhaled 
steroids should be based on factors other than efficacy in 
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TABLE 3. Incidence of treatment-related adverse events during two clinical trials of hydrofluoroalkane beclomethasone 
dipropionate (HFA-BDP) and fluticasone propionate (FP): respiratory system and application site disorders 
Study 1 - low dose Study 2 - high dose 
comparison (24) comparison (25) 
Adverse event 
HFA-BDP FP HFA-BDP FP 
400 pg day-’ 400 pg day- ’ 800 pg day-’ lOOOpgday-’ 
(n=88) (%) (n=84) (%) (n=lOl) (%) (n=97) (%) 
Fungal infection (oropharyngeal) 2.3 1.2 4.0 3.1 
Inhalation site sensation 1.1 2.4 1.0 3.1 
Dysphonia 0 1.2 1.0 3.1 
Cough 0 2.4 1.0 1.0 
Inhalation-associated increased asthma symptoms I.1 0 1.0 1.0 
Inhalation taste sensation 1.1 0 0 1.0 
Laryngitis 0 1.2 
Pharyngitis 1.1 0 1.0 0 
Upper respiratory tract infection 0 1.2 0 0 
Bronchitis 1.1 0 0 0 
Increased asthma symptoms 1.1 0 0 0 
controlling asthma. Price, side-effect profiles and the 
patient’s personal preference are important variables for 
the physician to consider when making this choice. 
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